

1 **ADHD 24/7: Circadian Clock Genes, Chronotherapy and Sleep/Wake Cycle**

2 **Insufficiencies in ADHD**

3
4 Maria Korman¹, Denise Palm², Adriana Uzoni², Frank Faltraco², Oliver Tucha³, Johannes
5 Thome², Andrew N. Coogan⁴

6
7 Institute: (1) The Edmond J. Safra Brain Research Center for the Study of Learning
8 Disabilities, University of Haifa, Haifa, Israel; (2) Department of Psychiatry and
9 Psychotherapy, University Medical Center Rostock, Rostock, Germany; (3) Department of
10 Clinical and Developmental Neuropsychology, Faculty of Behavioural and Social Sciences,
11 University of Groningen, The Netherlands; (4) Department of Psychology, Maynooth
12 University, National University of Ireland.

13
14 For correspondence:

15 Maria Korman
16 University of Haifa
17 199 Aba Khoushy Ave. Mount Carmel,
18 Haifa
19 ISRAEL
20 korman.maria@gmail.com

21
22
23 Running Title:

24 **ADHD 24/7**

25
26 Key words:

27 Attention-Deficit Hyperactivity Disorder, Chronotype, Circadian Genes, Light Therapy,
28 Fibroblasts

30 Abbreviations:

31 ADHD: Attention-Deficit Hyperactivity Disorder,

32 BL: Bright Light,

33 DSPD: Delayed Sleep Phase Disorder,

34 DLMO: Dim Light Melatonin Onset,

35 DSWPP: Delayed Sleep-Wake Phase Disorder,

36 EEG: Electroencephalogram,

37 ipRGCs: Intrinsically Photosensitive Retinal Ganglion Cells,

38 LT: Light Therapy,

39 N24SWD: Non 24 hour Sleep-Wake Rhythm Disorder,

40 SAD: Seasonal Affective Disorder,

41 SCN: Suprachiasmatic Nucleus,

42 SOI: Sleep Onset Insomnia,

43 SWD: Shift Work Disorder

44

45

46

47

48

49

50

51 **Abstract:**

52 *Objectives.* The current paper addresses the evidence for circadian clock characteristics
53 associated with Attention-Deficit Hyperactivity Disorder (ADHD), and possible therapeutic
54 approaches based on chronomodulation through bright light therapy. *Methods.* We review the
55 data reported in ADHD on genetic risk factors for phase-delayed circadian rhythms and on
56 the role of photic input in circadian re-alignment. *Results.* Single nucleotide polymorphisms
57 (SNPs) in circadian genes were recently associated with core ADHD symptoms, increased
58 evening-orientation and frequent sleep problems. Additionally, alterations in exposure and
59 response to photic input may underlie circadian problems in ADHD. Bright light (BL)
60 therapy was shown to be effective for re-alignment of circadian physiology toward
61 morningness, reducing sleep disturbances and bringing overall improvement in ADHD
62 symptoms. The susceptibility of the circadian system to phase shift by timed BL exposure
63 may have broad cost-effective potential implications for the treatment of ADHD.
64 *Conclusions.* We conclude that further research of circadian function in ADHD should focus
65 on detection of genetic markers (e.g., using human skin fibroblasts) and development of BL-
66 based therapeutic interventions.

67

68

69 **Introduction**

70 There is a substantial literature linking dysfunction of the circadian timing system to
71 the etiology and/or symptomatology of common neuropsychiatric disorders (Foster et al.,
72 2013). Such evidence includes the use of *ex vitro* models for the monitoring of circadian
73 rhythms in gene expression (Brown et al., 2005; Hida et al., 2017), behavioral monitoring
74 through the use of actigraphy (Ancoli-Israel et al., 2003) and the assessment of other
75 physiological, endocrine and psychological rhythmic processes (Refinetti, Lissen, & Halberg,
76 2007). The relevance of the circadian system to neuropsychiatric disorders is further
77 supported by genetic association studies (Kalman, Garbett, Janka, & Mirnics, 2016). One
78 such disorder is Attention Deficit Hyperactivity Disorder (ADHD).

79 Attention-deficit hyperactivity disorder (ADHD) is a neuropsychiatric condition
80 characterized by inattention and/or hyperactivity-impulsivity that interferes with everyday
81 functioning (Douglas, 1999; Kaiser, Schoemaker, Albaret, & Geuze, 2014). Based on the
82 prevailing symptomatology, ADHD has three presentations: (i) predominantly inattentive -,
83 (ii) predominantly hyperactive-impulsive -, and (iii) combined -(Gaub & Carlson, 1997).
84 ADHD, although a childhood-onset neurodevelopmental condition, is nevertheless a frequent
85 and disabling condition in adults (Magnin & Maurs, 2017) due to the relatively high
86 persistence rates of 40-50% (Lara et al. 2009). The prevalence of ADHD is around 5.3-7%
87 for children and adolescence, and 3.4-4.4% for adults (Polanczyk et al. 2007, Fayyad et al.
88 2007, Polanczyk and Rohde 2007). Although the etiology of ADHD remains poorly
89 understood, ADHD in all age groups has a strong genetic component (Franke et al., 2011).

90 While attention problems are recognized as a core deficit (Douglas, 1999), deficits in
91 executive functions (e.g., planning, inhibition and set-shifting) (Pennington & Ozonoff,
92 1996), motor functioning (Adi-Japha, Fox, & Karni, 2011; Goulardins, Marques, & De
93 Oliveira, 2017; Kaiser, et al., 2014; Mostofsky et al., 2006), skill learning ("how to" memory)

94 (Adi-Japha, et al., 2011; Korman, Levy, & Karni, 2017; Mostofsky, et al., 2006; Nicolson &
95 Fawcett, 2007), emotional instability (Petrovic & Castellanos, 2016) and sleep problems
96 (Philipsen, Hornyak, & Riemann, 2006) are recognized as additional key characteristics.

97 The symptomatology of ADHD may be positively influenced by shifting misaligned
98 circadian rhythms to more appropriate phase, through pharmacological or behavioural
99 interventions (Mayer et al., 2018). A successful therapy to influence the circadian rhythm via
100 changes in the expression of relevant genes, for example, in seasonal depression, is bright
101 light (BL) therapy, and thus it might be useful for the treatment of ADHD (Kaladchibachi &
102 Fernandez, 2018; Pail et al., 2011). A recent position paper of physicians and researchers
103 from the EU has addressed the need to explore and develop light based interventions to
104 ameliorate ADHD (Coogan, Baird, Popa-Wagner, & Thome, 2016).

105 Neurophysiological underpinnings of behavioural manifestations of the ADHD were
106 linked to brain structures such as the dorsal lateral prefrontal cortex, ventral lateral prefrontal
107 cortex, insula, anterior cingulate, and dysfunction of dopaminergic systems (Sowell et al.,
108 2003; Tripp & Wickens, 2008). Stimulants, such as methylphenidate, and atomoxetine are
109 currently the most common pharmacological treatments for ADHD (Chan, Fogler, &
110 Hammerness, 2016). Appropriate doses of stimulants increasing dopamine's availability
111 effectively improve attention, decrease hyperactivity, increase behaviour management and
112 improve executive functions in individuals with ADHD (Advokat, 2010; Arnsten, 2006;
113 Rubia et al., 2014; Spencer et al., 2013). Serious adverse events are very rare, but a high
114 proportion, up to 50%, of stimulant users suffers a range of non-serious adverse events,
115 which may explain the relatively high withdrawal rates (6-17%) (Storebo et al., 2018).
116 Moreover, some patients are unresponsive to stimulant medications. Most common non
117 serious short-term and long-term adverse effects include insomnia and other sleep problems,
118 headache, abdominal pain and poor appetite (Graham & Coghill, 2008; Storebo, et al., 2018).

119 Non-stimulants, such as atomoxetine may affect cardiovascular parameters, but do not affect
120 sleep (Graham & Coghill, 2008). These recently reported numbers call to investigate what is
121 the cost of such “non-serious” but chronic sleep problems and meal mis-timings due to
122 medications. How these problems are related to the inherent, treatment independent problems
123 with sleep and late chronotype in significant proportion of ADHD patients across the lifespan
124 (Coogan & McGowan, 2017)?

125 In the current review we aim underscore the importance of continuing the search for
126 biological markers of ADHD and incorporation of non-pharmacological modalities in
127 treatment protocols utilizing chronobiological perspective on ADHD etiology. We
128 hypothesize that patients with ADHD are candidates for a novel clinical approach that
129 includes a confirmatory laboratory evaluation, incorporating clock gene-based diagnosis and
130 circadian behavioural and biomarker’s testing. We propose that the use of Light Therapy
131 (LT) has a potential to induce short-term and long-term improvements in cognitive,
132 behavioural and emotional measures in patients with ADHD. Our review suggests a potential
133 directive in encouraging research to 1) determine the benefits of coupling fibroblasts’ genes
134 expression phase markers with cognitive (e.g., reaction time) and physiological markers (e.g.,
135 melatonin, cortisol) as a multi-dimensional diagnostic method of circadian dysregulation in
136 ADHD; 2) evaluating whether appropriately timed LT is a potent sleep, cognitive and
137 emotional enhancer in ADHD, either directly or mediated via circadian phase shifting. In
138 particular, of interest are the differential effects of three principally different light protocols
139 (natural light, blue light and dawn-like gradually changing light) on the short- and long-term
140 cognitive and emotional functional outcomes; and 3) evaluating, through randomized,
141 placebo-controlled studies, the relative effectiveness of light therapy compared to standard
142 pharmacological therapy to treat ADHD symptoms. We conclude that LT interventions that
143 independently or in conjunction with pharmacological treatment may improve core

144 symptomatology of ADHD or compensate for common adverse effect of stimulant
145 medications, primarily, sleep insufficiency, is of highest clinical importance. Moreover, LT
146 has the potential for augmentation or even prevention of psychiatric comorbidities in adult
147 ADHD, such as sleep and mood disorders.

148 The review starts with an overview of sleep and circadian rhythm dysfunction in
149 ADHD. Next, we describe the maintenance of the circadian timekeeping system “by” clock
150 genes, and its modulation by photic input. Recent findings unveiling the connection between
151 the circadian function and clock genes in different psychiatric disorders and in ADHD,
152 including the fibroblasts model, are summarized in the core part of the paper. In the
153 concluding section, light therapy for circadian alignment in ADHD and future directions of
154 integrated research, diagnosis and treatment are discussed.

155 **ADHD, sleep and circadian rhythm dysfunction**

156 ADHD in adolescents and adults is associated with the evening chronotype (Baird,
157 Coogan, Siddiqui, Donev, & Thome, 2012; Bumb et al., 2016; Coogan & McGowan, 2017;
158 Vogel et al., 2017), with ADHD individuals displaying preference for late sleep timing and,
159 accordingly, late timing of awakening. While more than 40% of adults with ADHD display
160 an evening preference, only about 11% of age-matched healthy peers show this preference
161 (Rybak, McNeely, Mackenzie, Jain, & Levitan, 2007). Greater eveningness is associated with
162 shorter night sleep periods. Consequently, a sleep debt may play a causal role in the core
163 symptoms of inattention and increased impulsivity (Rybak, et al., 2007). The hyperactivity of
164 ADHD patients is expressed in greater motility at night-time and may lead to sleep
165 deprivation (Philipsen, 2006). Also, seasonal affective disorder (SAD), a type of depression
166 disorder directly linked to circadian disruption, shows high comorbidity with ADHD
167 (Wynchank et al., 2016). The core symptoms of ADHD, such as inattention, impulsivity and
168 impatience, are typical outcomes of sleep deprivation even in typical adults (Corkum,

169 Tannock, & Moldofsky, 1998). As many as 70% of children and up to 83% of adults with
170 ADHD have been reported as having sleep problems (Philipsen, et al., 2006) with sleep onset
171 insomnia (SOI) being the most common problem (Van der Heijden, Smits, Van Someren, &
172 Gunning, 2005). Adults with ADHD also report reduced sleep quality, meaning difficulties in
173 falling asleep and in waking up (Kooij & Bijlenga, 2013). More than 60% of adults with
174 ADHD report increased sleepiness during day-time (Kooij & Bijlenga, 2013; Van der
175 Heijden, et al., 2005; Van Veen, Kooij, Boonstra, Gordijn, & Van Someren, 2010).
176 Interestingly, neurobiological delayed timing of melatonin secretion is found in children and
177 adults with ADHD (Van der Heijden, et al., 2005; Van Veen, et al., 2010). Sleep problems
178 and ADHD seem to interact in a complex bidirectional manner with sleep disturbances
179 exacerbating ADHD symptoms and ADHD symptoms exacerbating sleep disturbances
180 (Owens et al., 2013). In normally developed adults, sleep after practicing a new motor skill,
181 supports memory consolidation processes, contributing to the generation of stable, enhanced
182 and long lasting procedural memory representations (Debas et al., 2010; Korman, Raz, Flash,
183 & Karni, 2003), but when applying the protocols developed for normally developed controls
184 to adults with ADHD, overnight motor memory consolidation is hampered (Adi-Japha, et al.,
185 2011; Fox, Karni, & Adi-Japha, 2016; Korman, et al., 2017).

186 ADHD is also associated with disrupted regulation of arousal during wake (Brennan
187 & Arnsten, 2008; Hegerl & Hensch, 2014). Arousal is the physiological and psychological
188 state of being awoken or of sense organs stimulated to a point of perception (Schachter,
189 1964). Individuals with ADHD tend to be under-aroused in “normal” performance and
190 learning conditions (James, Cheung, Rijdsdijk, Asherson, & Kuntsi, 2016; Wainstein et al.,
191 2017; Zentall & Zentall, 1983). An optimal arousal level is considered a prerequisite for
192 successful cognition functioning (Yerkes & Dodson, 1908; Zentall & Zentall, 1983).
193 Cognitive theories of ADHD, such as the state regulation model (van der Meere, 2005) and

194 dual-process models (Halperin & Schulz, 2006; Johnson et al., 2007) propose that the high
195 within-subject fluctuations of cognitive performance in ADHD may reflect problems in
196 regulating arousal. Unstable and low arousal results in the inability or difficulty to sustain
197 attention on any task of waning novelty (Sikstrom & Soderlund, 2007; Strauss et al., 2018).
198 Resting EEG parameters of arousal level (Strauss, et al., 2018) and arousal stability (Sander,
199 Arns, Olbrich, & Hegerl, 2010; Strauss, et al., 2018) were recently suggested as biomarkers
200 for adult and paediatric ADHD. The restless behaviour of individuals with ADHD during
201 wake is interpreted as self-stimulation in order to raise their arousal level (Baijot et al., 2016;
202 Strauss, et al., 2018) and, consequently, performance. Altogether, altered circadian
203 functioning is associated with ADHD (Coogan & McGowan, 2017), suggesting that inner,
204 biological time-keeping malfunction may be an important factor in this clinical condition.

205 **The circadian timekeeping system is generated by “clock” genes**

206 The circadian timekeeping system underpins the generation of near 24-hour rhythms
207 of variations in physiology and behavior. These cycles are not a response to the changes in
208 the light or temperature around us: they are genetically encoded in a cell-autonomous
209 manner, and at a systems level the circadian timekeeping is the result of a hierarchical, highly
210 distributed whole organism system (Albrecht, 2012). The circadian clock cycle continues
211 running, in the absence of periodic environmental stimuli, to best synchronize physiology and
212 behavior, and with reference to the external environment, to the earth’s rotation (Duffy,
213 Rimmer, & Czeisler, 2001). However, the circadian clock can only reliably fulfil its function
214 in a constantly changing environment if it is synchronized (“entrained”) to appropriate
215 temporal cues in the environment. For mammals, the most important entraining stimulus
216 (“zeitgeber”) is light (Hughes, Jagannath, Hankins, Foster, & Peirson, 2015). Other non-
217 photic day time events, such as meal timing and social cues may also serve as zeitgebers,

218 although under normal circumstances light is setting circadian phase (Roenneberg & Mellow,
219 2016).

220 The master circadian clock is located in the suprachiasmatic nucleus (SCN) of the
221 hypothalamus (Moore, 1997; Reppert & Weaver, 2002). The SCN comprises a cell-
222 autonomous oscillatory network of synchronized individual clock neurons, which projects its
223 rhythm onto cell-autonomous clocks throughout the brain and peripheral tissues (Welsh,
224 Takahashi, & Kay, 2010). A subset of SCN neurons are stimulated by photic input
225 transmitted via the retinohypothalamic tract. The retinal receptors (intrinsically
226 photosensitive retinal ganglion cells (ipRGCs)) are specialized cells independent of the visual
227 system. The signal is monosynaptical propagated using glutamate as a transmitter. This
228 results in activation of the retinal receptors through modulating the electrophysiological
229 properties. (Welsh, et al., 2010). Moreover, SCN neurones display circadian rhythms in their
230 electrophysiological properties, and these electrophysiological rhythms are underpinned by
231 circadian clock genes (Belle, Diekman, Forger, & Piggins, 2009). At the molecular level,
232 circadian rhythms are generated via feedback loops involving a panel of clock genes and their
233 protein products (Albrecht, 2012).

234 At the molecular level, circadian rhythms are generated via feedback loops involving
235 a panel of clock genes and their protein products (Albrecht, 2012). The most important
236 circadian genes include circadian-locomotor output-cycle kaput-genes (Clock), brain and
237 muscle-Arnt-like 1 gene (Bmal1), periodic homolog genes (Per1/2/3) and cryptochrome
238 genes (Cry1/2) (Sato et al., 2006). The transcription factors CLOCK and BMAL1
239 heterodimerize and consequently bind to the promotor region of PER and CRY resulting in
240 activation of these genes. After translation and transcription, PER and CRY proteins are
241 gradually stabilized during the day and inhibit the activity of CLOCK and BMAL1. The
242 result of this negative feedback loop is the inhibition in the expression of PER and CRY (Lee,

243 Etchegaray, Cagampang, Loudon, & Reppert, 2001; Shearman et al., 2000). After 24 hours
244 one cycle is finished and the process starts again. CLOCK and BMAL1 are not only involved
245 in the activation of PER and CRY. Both activate clock-controlled genes in different
246 peripheral tissues (Janich et al., 2011; Marcheva et al., 2010; Paschos et al., 2012). This
247 circadian clock gene cycle has a widespread influence on the transcriptome, with 40% of all
248 mammalian genes showing circadian rhythms in their expression in at least one tissue
249 (Zhang, Lahens, Ballance, Hughes, & Hogenesch, 2014).

250 The SCN is rather a “master synchronizer” than a pacemaker. Most tissues show
251 circadian patterns of gene expression when cultured, although such rhythms dampen over a
252 number of days (Buhr & Takahashi, 2013). The SCN communicates with peripheral clocks
253 over several pathways, including hormonal cues (glucocorticoids, melatonin) and indirect
254 cues (body temperature, food intake; (Panda, 2016)). Each cue can phase-shift a peripheral
255 oscillator but may not alter the phase of the central clock, potentially leading to an internal
256 desynchrony of the circadian system, which in turn may lead to adverse outcomes
257 (Roenneberg & Merrow, 2016).

258 **Chronotype, Clock genes and ADHD**

259 One interesting pivot-point for the examination of genetic factors that may link
260 ADHD and circadian clocks is chronotype. Chronotype is usually measured as the
261 manifestation of preferred or actual timing of sleep/wake behaviour, and is shaped by
262 ontological, environmental and genetic factors (Adan et al, 2013). Later chronotype
263 (eveningness) is characterised by a later phase of entrainment of the endogenous circadian
264 system to environmental time cues resulting in later self-selected timing of sleep onsets and
265 offset, and morning types display an earlier phase of entrainment and converse effects on
266 sleep timing (Roenneberg et al, 2003). Chronotype may also be shaped by inter-individual
267 differences in sleep homeostasis, and as such should not be viewed as a purely circadian

268 phenomenon (Mongrain et al, 2006). Later chronotype is associated with a number of
269 psychopathological features in both clinical and non-clinical populations (Antypa et al, 2017;
270 Lemoine et al, 2017; Hsu et al, 2012). Chronotype has also been shown to influence a broad
271 range of cognitive functions, including the ADHD-relevant domains of attention
272 (eveningness associated with more inattention; Hennig et al, 2017) and impulsivity and risk-
273 taking (eveningness associated with more impulsive behaviours; McGowan et al, 2016; Ponzi
274 et al, 2014). The relative advantage of assessing chronotype over other circadian parameters
275 is that it can be reliably measured using validated questionnaires, and as such is more
276 scaleable than other approaches such as actigraphy or physiological and molecular measures
277 (Adan et al, 2012).

278 As mentioned previously, ADHD is associated with late chronotype, possibly
279 indicating a later entrained phase of the clock, altered sleep homeostasis, or an interaction
280 between the two (Coogan & McGowan, 2017). Similar to other behavioural traits,
281 chronotype is found to be heritable, with reported rates of heritability from family and
282 twin-studies in the range of 21% (Evans et al, 2011) to 40-50% (von Schantz et al, 2015;
283 Barclay et al, 2010). The putative genetic basis of chronotype has recently been explored in a
284 number of genome-wide association studies. Lane and colleagues (Lane et al., 2016) report
285 12 loci significant at the genome-wide level that are associated with chronotype in the UK
286 Biobank sample, including loci with previously described roles in the clock (PER2, an ASPS
287 gene, APH1A, RGS16 and FBXL13). These 12 loci accounted for 4.3% of the variance in the
288 extremities of chronotype, which in the UK BioBank is assessed by a single Likert 5 choice
289 self-assessment of diurnal preference (from the question “Do you consider yourself to be...”
290 and answers ranging from “Definitely a morning person” to “Definitely an evening person”).
291 A further study on the UK BioBank cohort reported 16 significant loci associated with
292 morningness, including ones near PER2 and RGS16 which is involved in phototransduction

293 (Jones et al., 2016). Hu and colleagues (Hu et al., 2016) report 15 loci associated with
294 morningness (assessed with two question parsed into a binary morning or evening responses
295 in the 23 and Me cohort), including 7 loci near genes with known circadian roles such as
296 those encoding vasoactive intestinal polypeptide (VIP), PER3, FBXL3 and hypocretin
297 receptor 2. Across these three studies, 9 loci were common in at least two studies, indicating
298 that genetic factors are important in shaping chronotype and that GWAS approaches are
299 insightful for this question (Kalmbach et al., 2017). Interestingly, a recent study has shown
300 overlap between genetic predisposition for eveningness and bipolar disorder (Melroy-Greif,
301 Gizer, Wilhelmsen, & Ehlers, 2017). Importantly, another recent study using umbilical
302 fibroblast have shown that factors associated with protein turnover are associated with
303 chronotype, indicating that circadian clock-non-specific factors may be important in
304 influencing clock dynamics and shaping chronotype (Gaspar et al., 2017).

305 Two of the GWAS analyses of the genetic architecture of chronotype also examined
306 genetic overlap between chronotype and ADHD: Lane et al (2016) reported no significant
307 genetic associations for chronotype with genetic risk for ADHD, and Jones et al (2016)
308 reported a similar null finding. Interestingly both studies do report significant associations for
309 the genetic risk scores for chronotype with those for schizophrenia. There are a number of
310 potential reasons for such observations. Firstly, the variance in chronotype accounted for by
311 the identified loci is modest (~4%, Lane et al, 2016), and chronotype is seemingly at most
312 50% heritable (von Schantz et al, 2015); as such the later chronotype reported in ADHD may
313 be behaviourally and environmental determined to a greater extent than genetically so. Such
314 an interpretation would situate phase-delays/late chronotype associated with ADHD more as
315 “egg” (i.e. results of other ADHD features) rather than as “chicken” (i.e. causal genetic
316 relationship from circadian to ADHD features). As such, delayed circadian phase as might be
317 indicated by later chronotype may provide a target for behavioural therapies designed to

318 counteract these phase shifts and ultimately to alleviate ADHD symptoms (see section 3).
319 Clock gene polymorphisms may not confer increased stand-alone genetic risk for ADHD
320 diagnosis, but may confer increased risk for ADHD symptom severity in interaction with
321 environmental factors; a recent report utilising random forest regression reported a significant
322 effect of PER3 in interaction with stress in predicting ADHD severity (van der Meer et al.,
323 2017). Another important caveat is that GWAS studies do not detect rare variants with a
324 minor allele frequency of <5% (Kalmbach et al, 2017). As such, rare variants that have been
325 reported to exert large effects on chronotype would not be captured in such analyses (Jones et
326 al, 1999; Patke et al, 2017). Targeted, hypothesis-driven genetic analysis may reveal roles for
327 such rare variants in ADHD. The final caveat in relation to GWAS studies of chronotype to
328 date is that circadian phenotyping has been based on only one or two questions generating
329 categorical scores based on diurnal preference, there is clear potential for loss of statistical
330 power and granularity in assessing subtleties of circadian phenotype that would not be
331 captured in such approaches (Kalmbach et al, 2017).

332 There are a number of older studies utilising analysis of single gene polymorphisms in
333 clock genes in ADHD samples. Whilst such studies have many well documented weaknesses,
334 including lack of statistical power, failure to account for epistasis and failure to replicate
335 (Farrell et al., 2015), it is interesting to note that specific polymorphisms in circadian genes
336 may result in very strong phenotypes. For example, an uncommon (allele frequency of ~0.1
337 to 0.6%) SNP in CRY1 leads to a gain-of-function mutation that results in a larger phase
338 delay of the rest/activity cycle that manifests as delayed sleep phase disorder (Patke et al.,
339 2017). A C/T SNP in the 3'-untranslated region of CLOCK rs1801260 was suggested to be
340 associated with chronotype in a candidate gene study (Katzenberg et al., 1998) (although see
341 (Iwase et al., 2002; Johansson et al., 2003; Pedrazzoli et al., 2007), and was subsequently
342 examined in adult ADHD. Kissling et al (2008) report that the T allele was a risk factor for

343 ADHD psychopathology in adults (Kissling et al., 2008). Xu and colleagues examined the
344 same SNP in adult ADHD and reported that the allele was overtransmitted in ADHD (Xu et
345 al., 2010). C allele in this SNP in CLOCK was also associated with ADHD symptoms in the
346 general population. This association was not mediated through chronotype (Jeong et al.,
347 2014). Of particular interest for these studies is a report that the rs1801260 SNP in CLOCK is
348 associated with altered CLOCK transcript stability and altered CLOCK protein expression;
349 therefore this is likely to be a functional mutation that alters the dynamics of the clock gene
350 cycle and circadian physiology (Shi et al., 2008).

351 Another clock gene polymorphism that has received considerable interest is the 4/5
352 variable number tandem repeat (VNTR) polymorphism in PER3 (Dijk & Archer, 2010). This
353 VNTR has been associated with chronotype, sleep homeostasis and various psychiatric
354 disorders (Archer et al., 2010). The VNTR in PER3 has been associated with difference in
355 executive function (planning performance assayed by the Tower-of-London task; (González-
356 Giraldo et al., 2015)). Further, a SNP in PER3 has recently been linked with ADHD in adults
357 (van der Meer, et al., 2017). As such, PER3 may represent an interesting locus for future
358 study in the genetic overlap between circadian function and ADHD. Other promising
359 associations with clock genes that may be pertinent to ADHD include an association with a
360 SNP in PER2 with reward in healthy adolescents (Forbes et al., 2012) and a SNP in PER1
361 predicting problematic alcohol use (Baranger et al., 2016). Future work will hopefully
362 address further the genetic overlap between the circadian system and ADHD, in order to
363 better understand the nature of the links between circadian timing and ADHD, and to offer
364 new targets for experimental monitoring and even therapeutic targeting.

365 The behavioural role of clock genes can be studied using reverse genetic approaches
366 in animal models, in which candidate genes are knocked out or altered (Morrow, Spoelstra, &
367 Roenneberg, 2005). A number of clock gene knockout animals show hyperactivity as part of

368 their behavioural phenotype, as well as various cognitive alterations. Mice carrying the
369 dominant negative CLOCK mutation show mania-like behaviour, including hyperactivity,
370 decreased sleep, lowered depression-like behaviour, reduced anxiety and an increased reward
371 value in association with elevated dopaminergic activities in the central tegmental area
372 (McClung et al., 2005; Roybal et al., 2007). However, this line of inquiry is complicated by
373 the lack of well validated animal models of ADHD, and the fact that hyperactivity as
374 observed in many models may be a highly non-specific phenotype and not particularly
375 relevant to ADHD-related processes (Carvalho, Vieira Crespo, Ferreira Bastos, Knight, &
376 Vicente, 2016).

377 A challenge in all studies of circadian function in humans is which, and how many,
378 phase biomarkers can and should be examined (Roenneberg & Mellow, 2016). Given that
379 SCN, and other central tissue, cannot be accessed in such studies as one would in animal
380 studies, investigators seek to assay peripheral oscillators that can be reasonably sampled. One
381 method is to measure circadian differences within and between populations in tissue biopsies
382 yielding primary skin fibroblasts. Individual circadian characteristics are manifested in both
383 central and peripheral oscillators (Brown, et al., 2005), and as such skin fibroblasts may serve
384 as useful substrate for the analysis of molecular circadian function. In fibroblasts transfected
385 with a *bm11::luciferase* reporter, period length is influenced by culture conditions (e.g.
386 temperature, concentration of serum in growth medium), but cells displaying short- and long-
387 period lengths retain their relative values under all conditions and period length is also
388 associated with chronotype (Brown, et al., 2005). Alterations in *per2::luc* rhythms have also
389 been reported in fibroblasts derived from patients with bipolar disorder, and these factors
390 predict responses to lithium (McCarthy et al., 2013). Recently, a study by Hida et al., showed
391 that an in vitro fibroblast rhythm assay accurately describes circadian behaviour of patients
392 with two types of circadian rhythm sleep disorders - delayed sleep-wake phase disorder

393 (DSWPD) and non-24-hour sleep–wake rhythm disorder (N24SWD) (Hida, et al., 2017).
394 Patients in this study received a four week chronotherapy (bright light therapy +
395 melatonin/melatonin receptor agonist administration). Longer in vitro period predicted poorer
396 response to chronotherapy in patients with N24SWD (Hida, et al., 2017). This and additional
397 studies (Vanselow et al., 2006), suggest that in vitro fibroblasts rhythm assays may provide a
398 valid tool to assess individual genetic characteristics in the biological clock of different
399 populations. Moreover, multiple pre- post- treatment fibroblast samples may contribute to the
400 evaluation of the efficacy of the phase-shifting treatments, including LT and melatonin
401 administration. To our best knowledge, there are no studies reporting usage of fibroblast
402 assays in ADHD diagnosis; given previous indications of clock gene expression changes in
403 ADHD (Baird, et al., 2012) such approaches may yield important insight into the alterations
404 of circadian processes at the molecular level in ADHD.

405 Cyclic production of pineal melatonin, released by the pineal gland in the absence of
406 blue light via the sympathetic system, informs the clock about photoperiod (e.g., day
407 length)(Stehle, von Gall, & Korf, 2003). As the sympathetic drive to the pineal is gated
408 through the SCN, the time of onset of melatonin biosynthesis under dim light conditions is a
409 very useful phase-marker (Keijzer, Smits, Duffy, & Curfs, 2014). Melatonin may play an
410 important role in the rhythmic clock gene expression (CLOCK, BMAL1, PER1-3, CRY1-2)
411 (Dardente et al., 2003; von Gall et al., 2005), and in various neurological functions and stress
412 response (Hardeland, Madrid, Tan, & Reiter, 2012). Exogenous melatonin and
413 melatonergic agonists are shown to entrain the sleep-wake cycle, advance endogenous
414 melatonin secretion and enhance total time asleep in children with ADHD and chronic sleep
415 onset insomnia (Chamorro, Lara, Insa, Espadas, & Alda-Diez, 2017; Van der Heijden, Smits,
416 Van Someren, Ridderinkhof, & Gunning, 2007). Further, adults with ADHD with chronic
417 sleep onset insomnia show delayed onset of melatonin secretion (Bijlenga et al., 2013; Van

418 Veen, et al., 2010), indicating a delayed phase in a SCN-derived signal. Other rhythmic
419 endocrine signals also show alterations in ADHD; cortisol, which shows a strong 24 rhythm
420 driven by the SCN, shows a phase-delay relative to wake-time in adult ADHD (Baird, et al.,
421 2012), and changes in the diurnal cortisol profiles have been linked with alterations in arousal
422 levels in children with ADHD (Imeraj et al., 2012). Therefore, assessment of rhythmic
423 endocrine function in ADHD, and its relationship to ADHD symptom severity and ADHD
424 medication, represents an important substrate for future investigation.

425 **Light treatment for circadian alignment**

426 Light is the primary synchronizer of the circadian timing system (Hughes, et al.,
427 2015). Visible light has a wavelength spectrum of 380 (violet) to 760 (red) nm. The intensity
428 of sunlight, depending on geographical location and season of the year, range between 7,000-
429 100,000 lux (Roenneberg, Kantermann, Juda, Vetter, & Allebrandt, 2013). The effects of
430 timing (Czeisler et al., 1986), duration (Chang et al., 2012), intensity (Boivin, Duffy,
431 Kronauer, & Czeisler, 1996) and wavelength (Revell, Arendt, Terman, & Skene, 2005) of
432 light stimuli on the human sleep-wake cycle are well established in a variety of measures,
433 including phase resetting and the suppression of the sleep promoting hormone, melatonin
434 (Chellappa, Gordijn, & Cajochen, 2011). The light-induced entraining is mediated via
435 intrinsically photosensitive retinal ganglion cells (ipRGCs) that project to the SCN in the
436 hypothalamus. The ipRGCs contain melanopsin, an opsin-like protein, most sensitive to blue
437 light (the shortest wavelength of the visual spectrum) (Hankins, Peirson, & Foster, 2008).
438 However, ipRGC light response is a composite one, influenced by both the extrinsic
439 (rod/cone) and the intrinsic (melanopsin) activation and ipRGC may play a role in visual
440 image formation (Allen, Storchi, Martial, Bedford, & Lucas, 2017). Light, via response of
441 ipRGCs to its spectral properties and intensity, induces a variety of non-visual responses, e.g.,

442 raising alertness, pupil constriction and suppression of pineal hormone melatonin release
443 (Debra & Josephine, 2006).

444 Thus, short wavelength blue light (460 nm) possesses greater phase shifting potential
445 than the rest of the visible light spectrum (Lockley et al., 2003, Warman et al., 2003, Wright
446 et al., 2004). Currently, there are no standardized guidelines for the application of light
447 therapy. Based on laboratory and field studies, light therapy should be sufficiently bright
448 (2,000-10,000 lux) to elicit a clinically significant response and should last long enough (>30
449 min) (van Maanen, Meijer, van der Heijden, & Oort, 2016). Blue light as an environmental
450 factor has been shown to be toxic to rod photoreceptors when the retina is exposed to either
451 high light intensities or to continuous light over a long period of time (Lack, Bramwell,
452 Wright, & Kemp, 2007; Youssef, Sheibani, & Albert, 2011). Therefore, long-term users of
453 bright light therapy lamps should be screened by ophthalmologists, and those with pre-
454 existing retinal conditions or other risk factors should abstain from bright light (BL) therapy
455 (Youssef, et al., 2011).

456 Natural daylight is considered the strongest zeitgeber for the circadian clock (Wright
457 et al., 2013). Effects of daylight are different from the artificial light and, in particular, BL
458 used in traditional light treatments, in several aspects. (i) In nature, dark-light transitions are
459 always gradual, giving biological systems time to adjust; graduate light exposure has been
460 shown to be an important factor in the photic entrainment of the biological clock (Endo,
461 Kripke, & Ancoli-Israel, 2015; Grandner, Kripke, Elliott, & Cole, 2013). Light-detecting
462 neurons in the circadian system have response characteristics suitable for detection of slow
463 changes in light intensity and spectrum during twilight (Endo, et al., 2015; Grandner, et al.,
464 2013; Usui, 2000). Exposure to BL, even through closed eyelids, was shown to be effective
465 for melatonin suppression (Figueiro, Plitnick, & Rea, 2014; Terman & Terman, 2006).
466 Studies that examined rhythm-entraining properties of artificial twilight and fluctuating light

467 intensity cycles, underscored the importance of gradual transition between light and darkness
468 for circadian rhythm entrainment in animal models and humans (Avery et al., 2001; Boulos,
469 Macchi, & Terman, 2002; Usui, 2000; Van De Werken et al., 2010). (ii) Colour (spectral)
470 qualities of natural daylight are rich and dynamically changing, while properties of BL used
471 in therapy protocols and in ambient artificial lighting are usually invariable and thus
472 biologically insufficient (Beute & de Kort, 2014; Hye Oh, Ji Yang, & Rag Do, 2014; Terman
473 & Terman, 1999). (iii) Cumulative amount of light during the day impacts human circadian
474 behavior - geographically defined amount of solar irradiation is linked to distributions of
475 chronotypes in population, with living at higher-latitudes areas predisposes to eveningness
476 (Leocadio-Miguel et al., 2017). In line with the latter, lower prevalence of ADHD was
477 recently associated with geographic areas of higher solar intensities (Arns, van der Heijden,
478 Arnold, & Kenemans, 2013). In general, modern people spend increasingly more time
479 indoors, where ambient light is orders of magnitude lower in intensity compared to outdoor
480 light on a clear day (Roenneberg, et al., 2013). Despite the importance of daylight for human
481 wellness and functionality, the neuropsychological consequences of exposure to natural light
482 in comparison to interventions using artificial light are currently poorly understood and the
483 potential of exposure to daylight has not been systematically evaluated both in healthy and
484 clinical populations. Thus, the mainstream of light treatment engages protocols of exposure to
485 artificially generated BL (Terman & Terman, 1999).

486 The susceptibility of the circadian clock to be shifted by time-specific light exposure
487 is thoroughly studied and is broadly utilized in treatment protocols of sleep-phase and
488 depressive disorders, e.g., SAD (Gooley, 2008; Kaladchibachi & Fernandez, 2018; Oldham
489 & Ciraulo, 2014). Long-term light interventions effectively advance sleep onset time (van
490 Maanen, et al., 2016; Watanabe, Kajimura, Kato, Sekimoto, & Takahashi, 1999) as well as
491 result in less sleepiness after awakening in neurotypical adults with DSPD (Lack, et al., 2007;

492 Van De Werken, et al., 2010), for a review see (Figueiro, 2016). Wu et al. (2009) treated
493 patients with bipolar disorder with three interventions: sleep deprivation, BL and sleep phase
494 advance. All three non-invasive interventions result in depression decrease (Wu et al., 2009).
495 A study with patients suffering from non-seasonal major depressive disorder observed a
496 positive effect of BL therapy, too. Treatment with BL, either as monotherapy or combined
497 with medication (fluoxetine) showed a consistent effect (Lam, Levitt, Levitan, & et al.,
498 2016). Simulated dawn was proposed as an adjunct and even alternative to BL therapy or
499 medication in the treatment of SAD (Avery, et al., 2001; Terman & Terman, 2006). In
500 addition to easing compliance, naturalistic dawn simulation eliminates possible ocular
501 adverse effects due to exposure to high intensity blue light of conventional BLT protocols
502 (Terman & Terman, 1999).

503 One inherent problem of bright light studies is the choice of an appropriate placebo
504 condition (Eastman, Young, Fogg, Liu, & Meaden, 1998). Several types of placebo or a
505 combination of them are used in placebo-controlled LT studies: dim red light (as opposed to
506 bright blue light), differently timed light (evening vs. morning), an inert placebo (a light box
507 emitting no visible light) or an inert (deactivated) negative ion generator (for examples see
508 (Chojnacka et al., 2016; Eastman, et al., 1998; Sit et al., 2018)). Indeed, due to the lack of an
509 obvious type of placebo treatment, LT studies have been extensively criticized for their
510 flawed experimental design. And yet, at least for the treatment of seasonal and non-seasonal
511 depression, an accumulated bulk of randomized and double-blind clinical trials approves the
512 utility of LT and invites further studies in other psychiatric, neurodevelopmental and
513 neurocognitive disorders (for review see (Kaladchibachi & Fernandez, 2018)).

514 Most patients with ADHD demonstrate delays in sleep-wake rhythms and
515 irregularities in melatonin and cortisol production times compared to healthy controls.
516 Considering the fact that ADHD has high co-morbidity with depression (Amons, Kooij,

517 Haffmans, Hoffman, & Hoencamp, 2006; Turgay & Ansari, 2006), is strongly associated
518 with delayed sleep phase syndrome (Amons, et al., 2006; Baird, et al., 2012; Coogan &
519 McGowan, 2017; Turgay & Ansari, 2006), and given an association between ADHD
520 prevalence and solar intensity at geographic loci (Arns, et al., 2013), the body of literature on
521 the effects of light therapy in ADHD is currently very limited.

522 A three-week trial of light therapy (LT) to a group of 29 adults with ADHD (Rybak,
523 McNeely, Mackenzie, Jain, & Levitan, 2006) used a full-spectrum fluorescent light box that
524 emitted 10,000 lux, for half an hour each morning, showed that morning BL therapy did help
525 alleviate subjective reports of deficits in maintaining effort and arousal, while improving
526 problems with inattention. Furthermore, neuropsychological testing further confirmed that LT
527 produced significant improvements on attentional functioning which was shown in basic
528 auditory attention span as well as for 2 key components of the Conner's' Continuous
529 Performance Test (CPT-II), indicating improvements in impulsivity and behavioural
530 inhibition. Circadian shift towards morningness was shown in many of the participants
531 (Rybak, et al., 2006).

532 A two-weeks LT in the morning (30-min morning 10,000 lux exposure 3h after mid-
533 sleep time) in pharmacologically treated participants with ADHD (with different, individually
534 prescribed drugs) significantly advanced the phase of dim light melatonin onset (DLMO) and
535 mid-sleep time (Fargason et al., 2017). These phase advances correlated with decreased total
536 scores in ADHD rating scales as well as hyperactivity-impulsivity indices (Fargason, et al.,
537 2017). Even a single week of LT (1h at 9:00 AM, 2500 lux) in adolescents with ADHD, who
538 were medicated (40 mg Methylphenidate daily) and engaged in psychotherapy, was
539 successful (Niederhofer, 2013). Behavioural improvements were found in both for the
540 Conner's inattention score and in the hyperactivity score. Moreover, evening melatonin
541 levels increased post-treatment (Niederhofer, 2013).

542 Compared to the long-term effects of light on human circadian rhythms, little
543 attention has been paid to its acute alerting action. High intensity light exposure acutely
544 reduces subjective sleepiness, improves well-being and neurobehavioral performance,
545 reduces attentional lapses, and activates the waking electroencephalogram (EEG) (Badia,
546 Myers, Boecker, Culpepper, & Harsh, 1991; Beute & de Kort, 2014). These alerting effects
547 appear to be dose dependent, such that higher illuminances have greater immediate effects
548 (Cajochen, Zeitzer, Czeisler, & Dijk, 2000). Significant advance of DLMO was shown
549 following a single morning exposure to BL during morning hours (>3000 lux) (Kozaki, Toda,
550 Noguchi, & Yasukouchi, 2011).

551 Surprisingly, light as acute alerting agent was not clinically studied in ADHD. We
552 hypothesize that exposure to BL in ADHD may produce effects similar to other types of
553 sensory stimulation during wakefulness. Various types of extra-task sensory stimulations
554 were reported beneficial for cognitive performance of children with ADHD, e.g., background
555 linguistic noise during a reading/arithmetic task (Zentall & Shaw, 1980), pictures during a
556 continuous performance auditory task (Zentall & Meyer, 1987), background music during
557 arithmetic tasks (Abikoff, Courtney, Szeibel, & Koplewicz, 1996) and auditory white noise
558 during a visually cued Go/NoGo task (Baijot, et al., 2016). If sensory stimulation in one or
559 more forms may enhance cognitive functioning of people with ADHD, similar acute effects
560 may be found for light treatment, especially given that light positively affects attention and
561 performance in neurotypical adults (Beute & de Kort, 2014).

562 It has been previously suggested that core cognitive processes, such as memory
563 consolidation, are extant but under-engaged in adults with ADHD and that this potential can
564 be unveiled in specific bio-behavioural conditions, contingent on the individual's chronotype
565 (Korman, et al., 2017), - e.g., by scheduling of training session to evening. A different,
566 chronotherapy approach by appropriately timed LT, may eliminate the need to adapt

567 conditions of training and performance to chronotype by long-term phase advancement of the
568 clock. LT is associated with dopaminergic (Kim et al., 2017), adrenergic (Bowrey, James, &
569 Aston-Jones, 2017) and serotonergic (Li, 2018) brain circuits activation, pathways directly
570 associated with learning, executive functioning and mood. The SCN's endogenous ~24h
571 time-generator comprises a dynamic series of functional brain states, which gate neuronal
572 plasticity following daily experiences. The circadian clock, the reward system, and memory
573 processes have many in common: light acts on all three systems through MAPK signalling
574 pathway (Iyer, Wang, & Gillette, 2014) and all three are affected by the HPA-axes via
575 cortisol, thereby leading to short-term changes (Albrecht, 2011; Eckel-Mahan et al., 2008).
576 Moreover, most clock genes are expressed in brain areas that are associated with learning,
577 memory, and reward (Albrecht, 2011), such as the amygdala (Lamont, Robinson, Stewart, &
578 Amir, 2005), the hippocampus (Jilg et al., 2010; Wakamatsu et al., 2001) and the ventral
579 tegmental area (Hampp et al., 2008).

580 **Conclusions**

581 ADHD is a common neuropsychiatric disorder affecting both wake and sleep phases
582 of the diurnal cycle. Altered function of clock genes in ADHD is so far poorly understood,
583 but mounting evidence suggests that atypical brain maturation and neurogenesis processes,
584 sleep problems and the emergence of cognitive, executive functioning and self-regulation
585 symptoms present in ADHD are at least partially subserved by circadian disruption (Charrier,
586 Olliac, Roubertoux, & Tordjman, 2017; Kobayashi, Ye, & Hensch, 2015). Thus, on the one
587 hand, studies showed that genetic risk factors exist, e.g., associations between ADHD and
588 other neuro-developmental and psychiatric disorders and polymorphism (rs1801260) at the
589 3'-untranslated region of the CLOCK gene, predispose to eveningness and sleep problems.
590 On the other hand, the susceptibility of the circadian system to phase shift by timed BL
591 exposure has broad cost-effective potential implications for the treatment of core symptoms

592 of ADHD as well as for augmentation for prevention of psychiatric comorbidities in ADHD.
593 Moreover, for the non-responders to pharmacological treatment, introduction of LT protocols
594 may be of utmost importance. Further studies are needed to evaluate therapeutic outcomes
595 of different types of light therapy (blue-light emitting boxes vs. simulated dawn vs. natural
596 daylight) and to explore causality between BL therapy and changes in circadian gene
597 expression. A suitable model for studying circadian gene expression and molecular circadian
598 function could be human skin fibroblasts. A recent study using BL therapy showed a poorer
599 response to chronotherapy predicted by longer in vitro period in patients with N24SWD
600 (Hida et al., 2017), suggesting that the period length is associated with chronotype and the
601 fibroblasts rhythm correlates with circadian behaviour. Combined approach of assessment
602 and phase shifting the circadian rhythm introduce new revenues for the integrated diagnosis,
603 treatment and the evaluation of treatment of ADHD.

604

605 **Acknowledgements:**

606 None

607 **Statement of interest:**

608 Johannes Thome has received financial support from pharmaceutical companies (Actelion,
609 Astra Zeneca, Bristol-Myers Squibb, EVER Neuro Pharma GmbH, Janssen-Cilag, Lilly,
610 Lundbeck, MEDICE, Merz, Novartis, Pfizer, Roche, Servier, Shire, Trommsdorff) some of
611 which manufacture medication used in the treatment of ADHD patients.

612 References

- 613 Abikoff, H., Courtney, M. E., Szeibel, P. J., & Koplewicz, H. S. (1996). The effects of auditory
614 stimulation on the arithmetic performance of children with ADHD and nondisabled children.
615 *J Learn Disabil*, 29(3), 238-246.
- 616 Adi-Japha, E., Fox, O., & Karni, A. (2011). Atypical acquisition and atypical expression of memory
617 consolidation gains in a motor skill in young female adults with ADHD. *Res Dev Disabil*,
618 32(3), 1011-1020.
- 619 Advokat, C. (2010). What are the cognitive effects of stimulant medications? Emphasis on adults with
620 attention-deficit/hyperactivity disorder (ADHD). *Neuroscience & Biobehavioral Reviews*,
621 34(8), 1256-1266.
- 622 Albrecht, U. (2011). The circadian clock, reward, and memory. *Front Mol Neurosci*, 4(41).
- 623 Albrecht, U. (2012). Timing to perfection: the biology of central and peripheral circadian clocks.
624 *Neuron*, 74(2), 246-260.
- 625 Allen, A. E., Storchi, R., Martial, F. P., Bedford, R. A., & Lucas, R. J. (2017). Melanopsin
626 Contributions to the Representation of Images in the Early Visual System. *Curr Biol*, 27(11),
627 1623-1632.
- 628 Amons, P. J., Kooij, J. J., Haffmans, P. M., Hoffman, T. O., & Hoencamp, E. (2006). Seasonality of
629 mood disorders in adults with lifetime attention-deficit/hyperactivity disorder (ADHD). *J*
630 *Affect Disord*, 91(2-3), 251-255.
- 631 Ancoli-Israel, S., Cole, R., Alessi, C., Chambers, M., Moorcroft, W., & Pollak, C. P. (2003). The role
632 of actigraphy in the study of sleep and circadian rhythms. *Sleep*, 26(3), 342-392.
- 633 Archer, S. N., Carpen, J. D., Gibson, M., Lim, G. H., Johnston, J. D., Skene, D. J., & von Schantz, M.
634 (2010). Polymorphism in the PER3 promoter associates with diurnal preference and delayed
635 sleep phase disorder. *Sleep*, 33(5), 695-701.
- 636 Arns, M., van der Heijden, K. B., Arnold, L. E., & Kenemans, J. L. (2013). Geographic variation in
637 the prevalence of attention-deficit/hyperactivity disorder: the sunny perspective. *Biol*
638 *Psychiatry*, 74(8), 585-590.
- 639 Arnsten, A. F. (2006). Stimulants: Therapeutic actions in ADHD. *Neuropsychopharmacology*, 31(11),
640 2376-2383.
- 641 Avery, D. H., Eder, D. N., Bolte, M. A., Hellekson, C. J., Dunner, D. L., Vitiello, M. V., & Prinz, P.
642 N. (2001). Dawn simulation and bright light in the treatment of SAD: a controlled study. *Biol*
643 *Psychiatry*, 50(3), 205-216.
- 644 Badia, P., Myers, B., Boecker, M., Culpepper, J., & Harsh, J. R. (1991). Bright light effects on body
645 temperature, alertness, EEG and behavior. *Physiol Behav*, 50(3), 583-588.
- 646 Baijot, S., Slama, H., Soderlund, G., Dan, B., Deltenre, P., Colin, C., & Deconinck, N. (2016).
647 Neuropsychological and neurophysiological benefits from white noise in children with and
648 without ADHD. *Behav Brain Funct*, 12(1), 016-0095.
- 649 Baird, A. L., Coogan, A. N., Siddiqui, A., Donev, R. M., & Thome, J. (2012). Adult attention-deficit
650 hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural,
651 endocrine and molecular levels. *Mol Psychiatry*, 17(10), 988-995.
- 652 Baranger, D. A., Ifrah, C., Prather, A. A., Carey, C. E., Corral-Frias, N. S., Drabant Conley, E., . . .
653 Bogdan, R. (2016). PER1 rs3027172 Genotype Interacts with Early Life Stress to Predict
654 Problematic Alcohol Use, but Not Reward-Related Ventral Striatum Activity. *Front Psychol*,
655 7(464).
- 656 Belle, M. D., Diekman, C. O., Forger, D. B., & Piggins, H. D. (2009). Daily electrical silencing in the
657 mammalian circadian clock. *Science*, 326(5950), 281-284.
- 658 Beute, F., & de Kort, Y. A. (2014). Salutogenic effects of the environment: review of health
659 protective effects of nature and daylight. *Appl Psychol Health Well Being*, 6(1), 67-95.
- 660 Bijlenga, D., Van Someren, E. J., Gruber, R., Bron, T. I., Kruithof, I. F., Spanbroek, E. C., & Kooij, J.
661 J. (2013). Body temperature, activity and melatonin profiles in adults with attention-
662 deficit/hyperactivity disorder and delayed sleep: a case-control study. *J Sleep Res*, 22(6), 607-
663 616.

- 664 Boivin, D. B., Duffy, J. F., Kronauer, R. E., & Czeisler, C. A. (1996). Dose-response relationships for
665 resetting of human circadian clock by light. *Nature*, *379*(6565), 540-542.
- 666 Boulos, Z., Macchi, M. M., & Terman, M. (2002). Twilights widen the range of photic entrainment in
667 hamsters. *J Biol Rhythms*, *17*(4), 353-363.
- 668 Bowrey, H. E., James, M. H., & Aston-Jones, G. (2017). New directions for the treatment of
669 depression: Targeting the photic regulation of arousal and mood (PRAM) pathway. *Depress*
670 *Anxiety*, *34*(7), 588-595.
- 671 Brennan, A. R., & Arnsten, A. F. (2008). Neuronal mechanisms underlying attention deficit
672 hyperactivity disorder: the influence of arousal on prefrontal cortical function. *Ann N Y Acad*
673 *Sci*, 007.
- 674 Brown, S. A., Fleury-Olela, F., Nagoshi, E., Hauser, C., Juge, C., Meier, C. A., . . . Schibler, U.
675 (2005). The period length of fibroblast circadian gene expression varies widely among human
676 individuals. *PLoS Biol*, *3*(10), 27.
- 677 Buhr, E. D., & Takahashi, J. S. (2013). Molecular components of the mammalian circadian clock.
678 *Handbook of experimental pharmacology*(217), 3-27. doi: 10.1007/978-3-642-25950-0_1
- 679 Bumb, J. M., Mier, D., Noelte, I., Schredl, M., Kirsch, P., Hennig, O., . . . Sobanski, E. (2016).
680 Associations of pineal volume, chronotype and symptom severity in adults with attention
681 deficit hyperactivity disorder and healthy controls. *Eur Neuropsychopharmacol*, *26*(7), 1119-
682 1126.
- 683 Cajochen, C., Zeitzer, J. M., Czeisler, C. A., & Dijk, D. J. (2000). Dose-response relationship for light
684 intensity and ocular and electroencephalographic correlates of human alertness. *Behav Brain*
685 *Res*, *115*(1), 75-83.
- 686 Carvalho, C., Vieira Crespo, M., Ferreira Bastos, L., Knight, A., & Vicente, L. (2016). Contribution
687 of animal models to contemporary understanding of Attention Deficit Hyperactivity Disorder.
688 *Altex*, *33*(3), 243-249.
- 689 Chamorro, M., Lara, J. P., Insa, I., Espadas, M., & Alda-Diez, J. A. (2017). Evaluation and treatment
690 of sleep problems in children diagnosed with attention deficit hyperactivity disorder: an
691 update of the evidence. *Rev Neurol*, *64*(9), 413-421.
- 692 Chan, E., Fogler, J. M., & Hammerness, P. G. (2016). Treatment of Attention-Deficit/Hyperactivity
693 Disorder in Adolescents: A Systematic Review. *JAMA*, *315*(18), 1997-2008.
- 694 Chang, A.-M., Santhi, N., St Hilaire, M., Gronfier, C., Bradstreet, D. S., Duffy, J. F., . . . Czeisler, C.
695 A. (2012). Human responses to bright light of different durations. *The Journal of Physiology*,
696 *590*(Pt 13), 3103-3112. doi: 10.1113/jphysiol.2011.226555
- 697 Charrier, A., Olliac, B., Roubertoux, P., & Tordjman, S. (2017). Clock Genes and Altered Sleep-
698 Wake Rhythms: Their Role in the Development of Psychiatric Disorders. *International*
699 *Journal of Molecular Sciences*, *18*(5), 938. doi: 10.3390/ijms18050938
- 700 Chellappa, S. L., Gordijn, M. C., & Cajochen, C. (2011). Can light make us bright? Effects of light on
701 cognition and sleep. *Prog Brain Res*, *190*, 119-133.
- 702 Chojnacka, M., Antosik-Wojcinska, A. Z., Dominiak, M., Bzinkowska, D., Borzym, A., Sokol-
703 Szawłowska, M., . . . Swieicki, L. (2016). A sham-controlled randomized trial of adjunctive
704 light therapy for non-seasonal depression. *J Affect Disord*, *203*, 1-8.
- 705 Coogan, A. N., Baird, A. L., Popa-Wagner, A., & Thome, J. (2016). Circadian rhythms and attention
706 deficit hyperactivity disorder: The what, the when and the why. *Progress in Neuro-*
707 *Psychopharmacology and Biological Psychiatry*, *67*(Supplement C), 74-81. doi:
708 <https://doi.org/10.1016/j.pnpbp.2016.01.006>
- 709 Coogan, A. N., & McGowan, N. M. (2017). A systematic review of circadian function, chronotype
710 and chronotherapy in attention deficit hyperactivity disorder. *Atten Defic Hyperact Disord*,
711 *7*(10), 016-0214.
- 712 Corkum, P., Tannock, R., & Moldofsky, H. (1998). Sleep disturbances in children with attention-
713 deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*, *37*(6), 637-646.
- 714 Czeisler, C. A., Allan, J. S., Strogatz, S. H., Ronda, J. M., Sanchez, R., Rios, C. D., . . . Kronauer, R.
715 E. (1986). Bright light resets the human circadian pacemaker independent of the timing of the
716 sleep-wake cycle. *Science*, *233*(4764), 667-671.

717 Dardente, H., Menet, J. S., Poirel, V. J., Streicher, D., Gauer, F., Vivien-Roels, B., . . . Masson-Pevet,
718 M. (2003). Melatonin induces Cry1 expression in the pars tuberalis of the rat. *Brain Res Mol*
719 *Brain Res*, *114*(2), 101-106.

720 Debas, K., Carrier, J., Orban, P., Barakat, M., Lungu, O., Vandewalle, G., . . . Doyon, J. (2010). Brain
721 plasticity related to the consolidation of motor sequence learning and motor adaptation.
722 *Proceedings of the National Academy of Sciences*, *107*(41), 17839-17844. doi:
723 10.1073/pnas.1013176107

724 Debra, J. S., & Josephine, A. (2006). Human circadian rhythms: physiological and therapeutic
725 relevance of light and melatonin. *Annals of Clinical Biochemistry*, *43*(5), 344-353. doi:
726 10.1258/000456306778520142

727 Dijk, D. J., & Archer, S. N. (2010). PERIOD3, circadian phenotypes, and sleep homeostasis. *Sleep*
728 *Med Rev*, *14*(3), 151-160.

729 Douglas, V. I. (1999). Cognitive Control Processes in Attention Deficit/Hyperactivity Disorder. In H.
730 C. Quay & A. E. Hogan (Eds.), *Handbook of Disruptive Behavior Disorders* (pp. 105-138).
731 Boston, MA: Springer US.

732 Duffy, J. F., Rimmer, D. W., & Czeisler, C. A. (2001). Association of intrinsic circadian period with
733 morningness-eveningness, usual wake time, and circadian phase. *Behavioral Neuroscience*,
734 *115*(4), 895-899. doi: 10.1037/0735-7044.115.4.895

735 Eastman, C. I., Young, M. A., Fogg, L. F., Liu, L., & Meaden, P. M. (1998). Bright light treatment of
736 winter depression: a placebo-controlled trial. *Arch Gen Psychiatry*, *55*(10), 883-889.

737 Eckel-Mahan, K. L., Phan, T., Han, S., Wang, H., Chan, G. C., Scheiner, Z. S., & Storm, D. R.
738 (2008). Circadian oscillation of hippocampal MAPK activity and cAmp: implications for
739 memory persistence. *Nat Neurosci*, *11*(9), 1074-1082.

740 Endo, T., Kripke, D. F., & Ancoli-Israel, S. (2015). Wake up time, light, and mood in a population
741 sample age 40-64 years. *Psychiatry Investig*, *12*(2), 177-182.

742 Fargason, R. E., Fobian, A. D., Hablitz, L. M., Paul, J. R., White, B. A., Cropsey, K. L., & Gamble,
743 K. L. (2017). Correcting delayed circadian phase with bright light therapy predicts
744 improvement in ADHD symptoms: A pilot study. *J Psychiatr Res*, *91*, 105-110.

745 Farrell, M. S., Werge, T., Sklar, P., Owen, M. J., Ophoff, R. A., O'Donovan, M. C., . . . Sullivan, P. F.
746 (2015). Evaluating historical candidate genes for schizophrenia. *Mol Psychiatry*, *20*(5), 555-
747 562.

748 Figueiro, M. G. (2016). Delayed sleep phase disorder: clinical perspective with a focus on light
749 therapy. *Nature and Science of Sleep*, *8*, 91-106. doi: 10.2147/nss.s85849

750 Figueiro, M. G., Plitnick, B., & Rea, M. S. (2014). Pulsing blue light through closed eyelids: effects
751 on acute melatonin suppression and phase shifting of dim light melatonin onset. *Nature and*
752 *Science of Sleep*, *6*, 149-156. doi: 10.2147/nss.s73856

753 Forbes, E. E., Dahl, R. E., Almeida, J. R., Ferrell, R. E., Nimgaonkar, V. L., Mansour, H., . . . Phillips,
754 M. L. (2012). PER2 rs2304672 polymorphism moderates circadian-relevant reward circuitry
755 activity in adolescents. *Biol Psychiatry*, *71*(5), 451-457.

756 Foster, R. G., Peirson, S. N., Wulff, K., Winnebeck, E., Vetter, C., & Roenneberg, T. (2013). Sleep
757 and circadian rhythm disruption in social jetlag and mental illness. *Prog Mol Biol Transl Sci*,
758 *119*, 325-346.

759 Fox, O., Karni, A., & Adi-Japha, E. (2016). The consolidation of a motor skill in young adults with
760 ADHD: Shorter practice can be better. *Res Dev Disabil*, *52*, 135-144.

761 Franke, B., Faraone, S. V., Asherson, P., Buitelaar, J., Bau, C. H. D., Ramos-Quiroga, J. A., . . . Reif,
762 A. (2011). The genetics of attention deficit/hyperactivity disorder in adults, a review. [Feature
763 Review]. *Molecular psychiatry*, *17*, 960. doi: 10.1038/mp.2011.138

764 Gaspar, L., Howald, C., Popadin, K., Maier, B., Mauvoisin, D., Moriggi, E., . . . Brown, S. A. (2017).
765 The genomic landscape of human cellular circadian variation points to a novel role for the
766 signalosome. *Elife*, *4*(6), 24994.

767 Gaub, M., & Carlson, C. L. (1997). Behavioral Characteristics of DSM-IV ADHD Subtypes in a
768 School-Based Population. *Journal of abnormal child psychology*, *25*(2), 103-111. doi:
769 10.1023/a:1025775311259

770 González-Giraldo, Y., González-Reyes, R. E., Mueller, S. T., Piper, B. J., Adan, A., & Forero, D. A.
771 (2015). Differences in planning performance, a neurocognitive endophenotype, are associated

772 with a functional variant in PER3 gene. *Chronobiology international*, 32(5), 591-595. doi:
773 10.3109/07420528.2015.1014096

774 Gooley, J. J. (2008). Treatment of circadian rhythm sleep disorders with light. *Ann Acad Med*
775 *Singapore*, 37(8), 669-676.

776 Goulardins, J. B., Marques, J. C., & De Oliveira, J. A. (2017). Attention Deficit Hyperactivity
777 Disorder and Motor Impairment. *Percept Mot Skills*, 124(2), 425-440.

778 Graham, J., & Coghill, D. (2008). Adverse Effects of Pharmacotherapies for Attention-Deficit
779 Hyperactivity Disorder. [journal article]. *CNS Drugs*, 22(3), 213-237. doi: 10.2165/00023210-
780 200822030-00003

781 Grandner, M. A., Kripke, D. F., Elliott, J., & Cole, R. (2013). Short wavelength light administered
782 just prior to waking: a pilot study. *Biol Rhythm Res*, 44(1), 13-32.

783 Halperin, J. M., & Schulz, K. P. (2006). Revisiting the role of the prefrontal cortex in the
784 pathophysiology of attention-deficit/hyperactivity disorder. *Psychol Bull*, 132(4), 560-581.

785 Hampp, G., Ripperger, J. A., Houben, T., Schmutz, I., Blex, C., Perreau-Lenz, S., . . . Albrecht, U.
786 (2008). Regulation of monoamine oxidase A by circadian-clock components implies clock
787 influence on mood. *Curr Biol*, 18(9), 678-683.

788 Hankins, M. W., Peirson, S. N., & Foster, R. G. (2008). Melanopsin: an exciting photopigment.
789 *Trends in Neurosciences*, 31(1), 27-36. doi: <https://doi.org/10.1016/j.tins.2007.11.002>

790 Hardeland, R., Madrid, J. A., Tan, D. X., & Reiter, R. J. (2012). Melatonin, the circadian
791 multioscillator system and health: the need for detailed analyses of peripheral melatonin
792 signaling. *J Pineal Res*, 52(2), 139-166.

793 Hegerl, U., & Hensch, T. (2014). The vigilance regulation model of affective disorders and ADHD.
794 *Neurosci Biobehav Rev*, 44, 45-57.

795 Hida, A., Ohsawa, Y., Kitamura, S., Nakazaki, K., Ayabe, N., Motomura, Y., . . . Mishima, K. (2017).
796 Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm
797 sleep disorders. *Transl Psychiatry*, 7(4), 75.

798 Hu, Y., Shmygelska, A., Tran, D., Eriksson, N., Tung, J. Y., & Hinds, D. A. (2016). GWAS of 89,283
799 individuals identifies genetic variants associated with self-reporting of being a morning
800 person. *Nat Commun*, 7(10448).

801 Hughes, S., Jagannath, A., Hankins, M. W., Foster, R. G., & Peirson, S. N. (2015). Photic regulation
802 of clock systems. *Methods Enzymol*, 552, 125-143.

803 Hye Oh, J., Ji Yang, S., & Rag Do, Y. (2014). Healthy, natural, efficient and tunable lighting: four-
804 package white LEDs for optimizing the circadian effect, color quality and vision
805 performance. [Original Article]. *Light: Science & Applications*, 3, e141. doi:
806 10.1038/lsa.2014.22

807 <https://www.nature.com/articles/lsa201422#supplementary-information>

808 Imeraj, L., Sonuga-Barke, E., Antrop, I., Roeyers, H., Wiersema, R., Bal, S., & Deboutte, D. (2012).
809 Altered circadian profiles in attention-deficit/hyperactivity disorder: an integrative review and
810 theoretical framework for future studies. *Neurosci Biobehav Rev*, 36(8), 1897-1919.

811 Iwase, T., Kajimura, N., Uchiyama, M., Ebisawa, T., Yoshimura, K., Kamei, Y., . . . Yamauchi, T.
812 (2002). Mutation screening of the human Clock gene in circadian rhythm sleep disorders.
813 *Psychiatry Res*, 109(2), 121-128.

814 Iyer, R., Wang, T. A., & Gillette, M. U. (2014). Circadian gating of neuronal functionality: a basis for
815 iterative metaplasticity. *Front Syst Neurosci*, 8(164).

816 James, S.-N., Cheung, C. H. M., Rijdsdijk, F., Asherson, P., & Kuntsi, J. (2016). Modifiable Arousal in
817 Attention-Deficit/Hyperactivity Disorder and Its Etiological Association With Fluctuating
818 Reaction Times. *Biological psychiatry*, 1(6), 539-547. doi: 10.1016/j.bpsc.2016.06.003

819 Janich, P., Pascual, G., Merlos-Suarez, A., Batlle, E., Ripperger, J., Albrecht, U., . . . Benitah, S. A.
820 (2011). The circadian molecular clock creates epidermal stem cell heterogeneity. *Nature*,
821 480(7376), 209-214.

822 Jeong, S. H., Yu, J. C., Lee, C. H., Choi, K. S., Choi, J. E., Kim, S. H., & Joo, E. J. (2014). Human
823 CLOCK gene-associated attention deficit hyperactivity disorder-related features in healthy
824 adults: quantitative association study using Wender Utah Rating Scale. *Eur Arch Psychiatry*
825 *Clin Neurosci*, 264(1), 71-81.

- 826 Jilg, A., Lesny, S., Peruzki, N., Schwegler, H., Selbach, O., Dehghani, F., & Stehle, J. H. (2010).
827 Temporal dynamics of mouse hippocampal clock gene expression support memory
828 processing. *Hippocampus*, *20*(3), 377-388.
- 829 Johansson, C., Willeit, M., Smedh, C., Ekholm, J., Paunio, T., Kieseppa, T., . . . Partonen, T. (2003).
830 Circadian clock-related polymorphisms in seasonal affective disorder and their relevance to
831 diurnal preference. *Neuropsychopharmacology*, *28*(4), 734-739.
- 832 Johnson, K. A., Kelly, S. P., Bellgrove, M. A., Barry, E., Cox, M., Gill, M., & Robertson, I. H.
833 (2007). Response variability in attention deficit hyperactivity disorder: evidence for
834 neuropsychological heterogeneity. *Neuropsychologia*, *45*(4), 630-638.
- 835 Jones, S. E., Tyrrell, J., Wood, A. R., Beaumont, R. N., Ruth, K. S., Tuke, M. A., . . . Weedon, M. N.
836 (2016). Genome-Wide Association Analyses in 128,266 Individuals Identifies New
837 Morningness and Sleep Duration Loci. *PLoS Genet*, *12*(8).
- 838 Kaiser, M. L., Schoemaker, M. M., Albaret, J. M., & Geuze, R. H. (2014). *What is the evidence of*
839 *impaired motor skills and motor control among children with attention deficit hyperactivity*
840 *disorder (ADHD)? Systematic review of the literature*: Res Dev Disabil. 2014 Nov
841 6;36C:338-357. doi: 10.1016/j.ridd.2014.09.023.
- 842 Kaladchibachi, S., & Fernandez, F. (2018). Precision Light for the Treatment of Psychiatric
843 Disorders. *Neural Plast*, *11*(5868570).
- 844 Kalman, S., Garbett, K. A., Janka, Z., & Mirnics, K. (2016). Human dermal fibroblasts in psychiatry
845 research. *Neuroscience*, *320*, 105-121.
- 846 Kalmbach, D. A., Schneider, L. D., Cheung, J., Bertrand, S. J., Kariharan, T., Pack, A. I., & Gehrman,
847 P. R. (2017). Genetic Basis of Chronotype in Humans: Insights From Three Landmark
848 GWAS. *Sleep*, *40*(2).
- 849 Katzenberg, D., Young, T., Finn, L., Lin, L., King, D. P., Takahashi, J. S., & Mignot, E. (1998). A
850 CLOCK polymorphism associated with human diurnal preference. *Sleep*, *21*(6), 569-576.
- 851 Keijzer, H., Smits, M. G., Duffy, J. F., & Curfs, L. M. (2014). Why the dim light melatonin onset
852 (DLMO) should be measured before treatment of patients with circadian rhythm sleep
853 disorders. *Sleep Med Rev*, *18*(4), 333-339.
- 854 Kim, J., Jang, S., Choe, H. K., Chung, S., Son, G. H., & Kim, K. (2017). Implications of Circadian
855 Rhythm in Dopamine and Mood Regulation. *Mol Cells*, *40*(7), 450-456.
- 856 Kissling, C., Retz, W., Wiemann, S., Coogan, A. N., Clement, R. M., Hunnerkopf, R., . . . Thome, J.
857 (2008). A polymorphism at the 3'-untranslated region of the CLOCK gene is associated with
858 adult attention-deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet*,
859 *147*(3), 333-338.
- 860 Kobayashi, Y., Ye, Z., & Hensch, T. K. (2015). Clock genes control cortical critical period timing.
861 *Neuron*, *86*(1), 264-275.
- 862 Kooij, & Bijlenga. (2013). The circadian rhythm in adult attention-deficit/hyperactivity disorder:
863 current state of affairs. (Journal Article).
- 864 Korman, Levy, I., & Karni, A. (2017). Procedural Memory Consolidation in Attention-
865 Deficit/Hyperactivity Disorder Is Promoted by Scheduling of Practice to Evening Hours.
866 [Original Research]. *Frontiers in Psychiatry*, *8*(140). doi: 10.3389/fpsyt.2017.00140
- 867 Korman, Raz, N., Flash, T., & Karni, A. (2003). Multiple shifts in the representation of a motor
868 sequence during the acquisition of skilled performance. *Proc Natl Acad Sci U S A*, *100*(21),
869 12492-12497. doi: 10.1073/pnas.2035019100
- 870 2035019100 [pii]
- 871 Kozaki, T., Toda, N., Noguchi, H., & Yasukouchi, A. (2011). Effects of different light intensities in
872 the morning on dim light melatonin onset. *J Physiol Anthropol*, *30*(3), 97-102.
- 873 Lack, L., Bramwell, T., Wright, H., & Kemp, K. (2007). Morning blue light can advance the
874 melatonin rhythm in mild delayed sleep phase syndrome. *Sleep and Biological Rhythms*, *5*(1),
875 78-80. doi: 10.1111/j.1479-8425.2006.00250.x
- 876 Lam, R. W., Levitt, A. J., Levitan, R. D., & et al. (2016). Efficacy of bright light treatment,
877 fluoxetine, and the combination in patients with nonseasonal major depressive disorder: A
878 randomized clinical trial. *JAMA Psychiatry*, *73*(1), 56-63. doi:
879 10.1001/jamapsychiatry.2015.2235

- 880 Lamont, E. W., Robinson, B., Stewart, J., & Amir, S. (2005). The central and basolateral nuclei of the
881 amygdala exhibit opposite diurnal rhythms of expression of the clock protein Period2.
882 *Proceedings of the National Academy of Sciences of the United States of America*, *102*(11),
883 4180-4184. doi: 10.1073/pnas.0500901102
- 884 Lane, J. M., Vlasac, I., Anderson, S. G., Kyle, S. D., Dixon, W. G., Bechtold, D. A., . . . Saxena, R.
885 (2016). Genome-wide association analysis identifies novel loci for chronotype in 100,420
886 individuals from the UK Biobank. *Nat Commun*, *7*(10889).
- 887 Lee, C., Etchegaray, J. P., Cagampang, F. R., Loudon, A. S., & Reppert, S. M. (2001).
888 Posttranslational mechanisms regulate the mammalian circadian clock. *Cell*, *107*(7), 855-867.
- 889 Leocadio-Miguel, M. A., Louzada, F. M., Duarte, L. L., Areas, R. P., Alam, M., Freire, M. V., . . .
890 Pedrazzoli, M. (2017). Latitudinal cline of chronotype. *Scientific Reports*, *7*(1), 5437. doi:
891 10.1038/s41598-017-05797-w
- 892 Li, X. (2018). The Antidepressant Effect of Light Therapy from Retinal Projections. *Neurosci Bull*,
893 *34*(2), 359-368.
- 894 Magnin, E., & Maurs, C. (2017). Attention-deficit/hyperactivity disorder during adulthood. *Rev*
895 *Neurol*, *173*(7-8), 506-515.
- 896 Marcheva, B., Ramsey, K. M., Buhr, E. D., Kobayashi, Y., Su, H., Ko, C. H., . . . Bass, J. (2010).
897 Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and
898 diabetes. *Nature*, *466*(7306), 627-631.
- 899 Mayer, J. S., Hees, K., Medda, J., Grimm, O., Asherson, P., Bellina, M., . . . Freitag, C. M. (2018).
900 Bright light therapy versus physical exercise to prevent co-morbid depression and obesity in
901 adolescents and young adults with attention-deficit / hyperactivity disorder: study protocol for
902 a randomized controlled trial. *Trials*, *19*(1), 017-2426.
- 903 McCarthy, M. J., Wei, H., Marnoy, Z., Darvish, R. M., McPhie, D. L., Cohen, B. M., & Welsh, D. K.
904 (2013). Genetic and clinical factors predict lithium's effects on PER2 gene expression
905 rhythms in cells from bipolar disorder patients. *Transl Psychiatry*, *22*(3), 90.
- 906 McClung, C. A., Sidiropoulou, K., Vitaterna, M., Takahashi, J. S., White, F. J., Cooper, D. C., &
907 Nestler, E. J. (2005). Regulation of dopaminergic transmission and cocaine reward by the
908 Clock gene. *Proc Natl Acad Sci U S A*, *102*(26), 9377-9381.
- 909 Melroy-Greif, W. E., Gizer, I. R., Wilhelmsen, K. C., & Ehlers, C. L. (2017). Genetic Influences on
910 Evening Preference Overlap with Those for Bipolar Disorder in a Sample of Mexican
911 Americans and American Indians. *Twin Res Hum Genet*, *20*(6), 499-510.
- 912 Merrow, M., Spoelstra, K., & Roenneberg, T. (2005). The circadian cycle: daily rhythms from
913 behaviour to genes. *First in the Cycles Review Series*, *6*(10), 930-935. doi:
914 10.1038/sj.embor.7400541
- 915 Moore, R. Y. (1997). Circadian rhythms: basic neurobiology and clinical applications. *Annu Rev Med*,
916 *48*, 253-266.
- 917 Mostofsky, S. H., Rimrodt, S. L., Schafer, J. G. B., Boyce, A., Goldberg, M. C., Pekar, J. J., &
918 Denckla, M. B. (2006). Atypical motor and sensory cortex activation in attention-
919 deficit/hyperactivity disorder: a functional magnetic resonance imaging study of simple
920 sequential finger tapping. *Biological psychiatry*, *59*(1), 48-56.
- 921 Nicolson, R. I., & Fawcett, A. J. (2007). Procedural learning difficulties: reuniting the developmental
922 disorders? *Trends in Neurosciences*, *30*(4), 135-141. doi: 10.1016/j.tins.2007.02.003
- 923 Niederhofer, H. (2013). Stabilization of Circadian Rhythm, Its Augmentation by Bright Light
924 Treatment and Its Importance for ADHD and Depression of Adolescents. *Neuroscience and*
925 *Medicine*, *Vol.04No.03*, 5. doi: 10.4236/nm.2013.43024
- 926 Oldham, M. A., & Ciraulo, D. A. (2014). Bright light therapy for depression: a review of its effects on
927 chronobiology and the autonomic nervous system. *Chronobiol Int*, *31*(3), 305-319.
- 928 Owens, J., Gruber, R., Brown, T., Corkum, P., Cortese, S., O'Brien, L., . . . Weiss, M. (2013). Future
929 research directions in sleep and ADHD: report of a consensus working group. *Journal of*
930 *attention disorders*, *17*(7), 550-564. doi: 10.1177/1087054712457992 [doi]
- 931 Pail, G., Huf, W., Pjrek, E., Winkler, D., Willeit, M., Praschak-Rieder, N., & Kasper, S. (2011).
932 Bright-light therapy in the treatment of mood disorders. *Neuropsychobiology*, *64*(3), 152-162.
- 933 Panda, S. (2016). Circadian physiology of metabolism. *Science*, *354*(6315), 1008-1015.

934 Paschos, G. K., Ibrahim, S., Song, W. L., Kunieda, T., Grant, G., Reyes, T. M., . . . Fitzgerald, G. A.
935 (2012). Obesity in mice with adipocyte-specific deletion of clock component Arntl. *Nat Med*,
936 18(12), 1768-1777.

937 Patke, A., Murphy, P. J., Onat, O. E., Krieger, A. C., Ozcelik, T., Campbell, S. S., & Young, M. W.
938 (2017). Mutation of the Human Circadian Clock Gene CRY1 in Familial Delayed Sleep
939 Phase Disorder. *Cell*, 169(2), 203-215.

940 Pedrazzoli, M., Louzada, F. M., Pereira, D. S., Benedito-Silva, A. A., Lopez, A. R., Martynhak, B. J.,
941 . . . Tufik, S. (2007). Clock polymorphisms and circadian rhythms phenotypes in a sample of
942 the Brazilian population. *Chronobiol Int*, 24(1), 1-8.

943 Pennington, B. F., & Ozonoff, S. (1996). Executive functions and developmental psychopathology. *J*
944 *Child Psychol Psychiatry*, 37(1), 51-87.

945 Petrovic, P., & Castellanos, F. X. (2016). Top-Down Dysregulation—From ADHD to Emotional
946 Instability. *Frontiers in Behavioral Neuroscience*, 10, 70. doi: 10.3389/fnbeh.2016.00070

947 Philipsen, A. (2006). Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder
948 (ADHD) and borderline personality disorder (BPD) in adults. *Eur Arch Psychiatry Clin*
949 *Neurosci*, 256(1), i42-46.

950 Philipsen, A., Hornyak, M., & Riemann, D. (2006). Sleep and sleep disorders in adults with attention
951 deficit/hyperactivity disorder. *Sleep Med Rev*, 10(6), 399-405.

952 Refinetti, R., Lissen, G. C., & Halberg, F. (2007). Procedures for numerical analysis of circadian
953 rhythms. *Biol Rhythm Res*, 38(4), 275-325.

954 Reppert, S. M., & Weaver, D. R. (2002). Coordination of circadian timing in mammals. *Nature*,
955 418(6901), 935-941.

956 Revell, V. L., Arendt, J., Terman, M., & Skene, D. J. (2005). *Short-wavelength sensitivity of the*
957 *human circadian system to phase-advancing light*: J Biol Rhythms. 2005 Jun;20(3):270-2.

958 Roenneberg, T., Kantermann, T., Juda, M., Vetter, C., & Allebrandt, K. V. (2013). Light and the
959 human circadian clock. *Handb Exp Pharmacol*, 217, 311-331.

960 Roenneberg, T., & Merrow, M. (2016). The Circadian Clock and Human Health. *Curr Biol*, 26(10),
961 011.

962 Roybal, K., Theobald, D., Graham, A., DiNieri, J. A., Russo, S. J., Krishnan, V., . . . McClung, C. A.
963 (2007). Mania-like behavior induced by disruption of CLOCK. *Proc Natl Acad Sci U S A*,
964 104(15), 6406-6411.

965 Rubia, K., Alegria, A. A., Cubillo, A. I., Smith, A. B., Brammer, M. J., & Radua, J. (2014). Effects of
966 stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review
967 and meta-analysis. *Biol Psychiatry*, 76(8), 616-628.

968 Rybak, Y. E., McNeely, H. E., Mackenzie, B. E., Jain, U. R., & Levitan, R. D. (2006). An open trial
969 of light therapy in adult attention-deficit/hyperactivity disorder. *J Clin Psychiatry*, 67(10),
970 1527-1535.

971 Rybak, Y. E., McNeely, H. E., Mackenzie, B. E., Jain, U. R., & Levitan, R. D. (2007). Seasonality
972 and circadian preference in adult attention-deficit/hyperactivity disorder: clinical and
973 neuropsychological correlates. *Compr Psychiatry*, 48(6), 562-571.

974 Sander, C., Arns, M., Olbrich, S., & Hegerl, U. (2010). EEG-vigilance and response to stimulants in
975 paediatric patients with attention deficit/hyperactivity disorder. *Clin Neurophysiol*, 121(9),
976 1511-1518.

977 Sato, T. K., Yamada, R. G., Ukai, H., Baggs, J. E., Miraglia, L. J., Kobayashi, T. J., . . . Hogenesch, J.
978 B. (2006). Feedback repression is required for mammalian circadian clock function. *Nat*
979 *Genet*, 38(3), 312-319.

980 Schachter, S. (1964). The Interaction of Cognitive and Physiological Determinants of Emotional
981 State
982 Much of the research described in this paper was supported by Grant MH 05203 from
983 the National Institute of Mental Health, United States Public Health Service, and by Grant G
984 23758 from the National Science Foundation. In L. Berkowitz (Ed.), *Advances in*
985 *Experimental Social Psychology* (Vol. 1, pp. 49-80): Academic Press.

985 Shearman, L. P., Sriram, S., Weaver, D. R., Maywood, E. S., Chaves, I., Zheng, B., . . . Reppert, S. M.
986 (2000). Interacting molecular loops in the mammalian circadian clock. *Science*, 288(5468),
987 1013-1019.

- 988 Shi, J., Wittke-Thompson, J. K., Badner, J. A., Hattori, E., Potash, J. B., Willour, V. L., . . . Liu, C.
989 (2008). Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian
990 rhythm. *Am J Med Genet B Neuropsychiatr Genet*, 5(7), 1047-1055.
- 991 Sikstrom, S., & Soderlund, G. (2007). Stimulus-dependent dopamine release in attention-
992 deficit/hyperactivity disorder. *Psychol Rev*, 114(4), 1047-1075.
- 993 Sit, D. K., McGowan, J., Wiltrout, C., Diler, R. S., Dills, J. J., Luther, J., . . . Wisner, K. L. (2018).
994 Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind
995 Placebo-Controlled Trial. *Am J Psychiatry*, 175(2), 131-139.
- 996 Sowell, E. R., Thompson, P. M., Welcome, S. E., Henkenius, A. L., Toga, A. W., & Peterson, B. S.
997 (2003). Cortical abnormalities in children and adolescents with attention-deficit hyperactivity
998 disorder. *Lancet*, 362(9397), 1699-1707.
- 999 Spencer, T. J., Brown, A., Seidman, L. J., Valera, E. M., Makris, N., Lomedico, A., . . . Biederman, J.
1000 (2013). Effect of psychostimulants on brain structure and function in ADHD: a qualitative
1001 literature review of magnetic resonance imaging-based neuroimaging studies. *J Clin*
1002 *Psychiatry*, 74(9), 902-917.
- 1003 Stehle, J. H., von Gall, C., & Korf, H. W. (2003). Melatonin: a clock-output, a clock-input. *J*
1004 *Neuroendocrinol*, 15(4), 383-389.
- 1005 Storebo, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., . . . Gluud,
1006 C. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children
1007 and adolescents - assessment of adverse events in non-randomised studies. *Cochrane*
1008 *Database Syst Rev*, 9(5).
- 1009 Strauss, M., Ulke, C., Paucke, M., Huang, J., Mauche, N., Sander, C., . . . Hegerl, U. (2018). Brain
1010 arousal regulation in adults with attention-deficit/hyperactivity disorder (ADHD). *Psychiatry*
1011 *Res*, 261, 102-108.
- 1012 Terman, M., & Terman, J. S. (1999). Bright light therapy: side effects and benefits across the
1013 symptom spectrum. *J Clin Psychiatry*, 60(11), 799-808.
- 1014 Terman, M., & Terman, J. S. (2006). Controlled trial of naturalistic dawn simulation and negative air
1015 ionization for seasonal affective disorder. *Am J Psychiatry*, 163(12), 2126-2133.
- 1016 Tripp, G., & Wickens, J. R. (2008). Research review: dopamine transfer deficit: a neurobiological
1017 theory of altered reinforcement mechanisms in ADHD. *J Child Psychol Psychiatry*, 49(7),
1018 691-704.
- 1019 Turgay, A., & Ansari, R. (2006). *Major Depression with ADHD: In Children and Adolescents:*
1020 *Psychiatry* (Edgmont). ;3(4):20-32.
- 1021 Usui, S. (2000). Gradual changes in environmental light intensity and entrainment of circadian
1022 rhythms. *Brain Dev*, 22(1), S61-64.
- 1023 Van De Werken, M., Gimenez, M. C., De Vries, B., Beersma, D. G., Van Someren, E. J., & Gordijn,
1024 M. C. (2010). Effects of artificial dawn on sleep inertia, skin temperature, and the awakening
1025 cortisol response. *J Sleep Res*, 19(3), 425-435.
- 1026 Van der Heijden, Smits, M. G., Van Someren, E. J., & Gunning, W. B. (2005). Idiopathic chronic
1027 sleep onset insomnia in attention-deficit/hyperactivity disorder: a circadian rhythm sleep
1028 disorder. *Chronobiol Int*, 22(3), 559-570.
- 1029 Van der Heijden, Smits, M. G., Van Someren, E. J., Ridderinkhof, K. R., & Gunning, W. B. (2007).
1030 Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset
1031 insomnia. *J Am Acad Child Adolesc Psychiatry*, 46(2), 233-241.
- 1032 van der Meer, D., Hoekstra, P. J., van Donkelaar, M., Bralten, J., Oosterlaan, J., Heslenfeld, D., . . .
1033 Hartman, C. A. (2017). Predicting attention-deficit/hyperactivity disorder severity from
1034 psychosocial stress and stress-response genes: a random forest regression approach. *Transl*
1035 *Psychiatry*, 7(6), 114.
- 1036 van der Meere, J. (2005). State regulation and attention deficit hyperactivity disorder. *Attention*
1037 *Deficit Hyperactivity Disorder From genes to patients*, 413-433.
- 1038 van Maanen, A., Meijer, A. M., van der Heijden, K. B., & Oort, F. J. (2016). The effects of light
1039 therapy on sleep problems: A systematic review and meta-analysis. *Sleep Med Rev*, 29, 52-62.
- 1040 Van Veen, M. M., Kooij, J. J. S., Boonstra, A. M., Gordijn, M. C. M., & Van Someren, E. J. W.
1041 (2010). Delayed Circadian Rhythm in Adults with Attention-Deficit/Hyperactivity Disorder

1042 and Chronic Sleep-Onset Insomnia. *Biological psychiatry*, 67(11), 1091-1096. doi:
1043 10.1016/j.biopsych.2009.12.032

1044 Vanselow, K., Vanselow, J. T., Westermarck, P. O., Reischl, S., Maier, B., Korte, T., . . . Kramer, A.
1045 (2006). Differential effects of PER2 phosphorylation: molecular basis for the human familial
1046 advanced sleep phase syndrome (FASPS). *Genes Dev*, 20(19), 2660-2672.

1047 Vogel, S. W. N., Bijlenga, D., Benjamins, J. S., Beekman, A. T. F., Kooij, J. J. S., & Van Someren, E.
1048 J. W. (2017). Attention deficit hyperactivity disorder symptom severity and sleep problems in
1049 adult participants of the Netherlands sleep registry. *Sleep Med*, 40, 94-102.

1050 von Gall, C., Weaver, D. R., Moek, J., Jilg, A., Stehle, J. H., & Korf, H. W. (2005). Melatonin plays a
1051 crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis.
1052 *Ann N Y Acad Sci*, 105.

1053 Wainstein, G., Rojas-Libano, D., Crossley, N. A., Carrasco, X., Aboitiz, F., & Ossandon, T. (2017).
1054 Pupil Size Tracks Attentional Performance In Attention-Deficit/Hyperactivity Disorder. *Sci*
1055 *Rep*, 7(1), 017-08246.

1056 Wakamatsu, H., Yoshinobu, Y., Aida, R., Moriya, T., Akiyama, M., & Shibata, S. (2001). Restricted-
1057 feeding-induced anticipatory activity rhythm is associated with a phase-shift of the expression
1058 of mPer1 and mPer2 mRNA in the cerebral cortex and hippocampus but not in the
1059 suprachiasmatic nucleus of mice. *Eur J Neurosci*, 13(6), 1190-1196.

1060 Watanabe, T., Kajimura, N., Kato, M., Sekimoto, M., & Takahashi, K. (1999). Effects of
1061 phototherapy in patients with delayed sleep phase syndrome. *Psychiatry Clin Neurosci*, 53(2),
1062 231-233.

1063 Welsh, D. K., Takahashi, J. S., & Kay, S. A. (2010). Suprachiasmatic Nucleus: Cell Autonomy and
1064 Network Properties. *Annual Review of Physiology*, 72(1), 551-577. doi: 10.1146/annurev-
1065 physiol-021909-135919

1066 Wright, K. P., McHill, A. W., Birks, B. R., Griffin, B. R., Rusterholz, T., & Chinoy, E. D. (2013).
1067 Entrainment of the Human Circadian Clock to the Natural Light-Dark Cycle. *Current biology*
1068 : *CB*, 23(16), 1554-1558. doi: 10.1016/j.cub.2013.06.039

1069 Wu, J. C., Kelsoe, J. R., Schachat, C., Bunney, B. G., DeModena, A., Golshan, S., . . . Bunney, W. E.
1070 (2009). Rapid and sustained antidepressant response with sleep deprivation and
1071 chronotherapy in bipolar disorder. *Biol Psychiatry*, 66(3), 298-301.

1072 Wynchank, D. S., Bijlenga, D., Lamers, F., Bron, T. I., Winthorst, W. H., Vogel, S. W., . . . Kooij, J.
1073 S. (2016). ADHD, circadian rhythms and seasonality. *J Psychiatr Res*, 81, 87-94.

1074 Xu, X., Breen, G., Chen, C.-K., Huang, Y.-S., Wu, Y.-Y., & Asherson, P. (2010). Association study
1075 between a polymorphism at the 3'-untranslated region of CLOCK gene and attention deficit
1076 hyperactivity disorder. [journal article]. *Behavioral and Brain Functions*, 6(1), 48. doi:
1077 10.1186/1744-9081-6-48

1078 Yerkes, R. M., & Dodson, J. D. (1908). The relation of strength of stimulus to rapidity of habit-
1079 formation. *Journal of Comparative Neurology and Psychology*, 18(5), 459-482. doi:
1080 10.1002/cne.920180503

1081 Youssef, P. N., Sheibani, N., & Albert, D. M. (2011). Retinal light toxicity. *Eye*, 25(1), 1-14. doi:
1082 10.1038/eye.2010.149

1083 Zentall, S. S., & Meyer, M. J. (1987). Self-regulation of stimulation for ADD-H children during
1084 reading and vigilance task performance. *J Abnorm Child Psychol*, 15(4), 519-536.

1085 Zentall, S. S., & Shaw, J. H. (1980). Effects of classroom noise on performance and activity of
1086 second-grade hyperactive and control children. *J Educ Psychol*, 72(6), 830-840.

1087 Zentall, S. S., & Zentall, T. R. (1983). Optimal stimulation: a model of disordered activity and
1088 performance in normal and deviant children. *Psychol Bull*, 94(3), 446-471.

1089 Zhang, R., Lahens, N. F., Ballance, H. I., Hughes, M. E., & Hogenesch, J. B. (2014). A circadian gene
1090 expression atlas in mammals: implications for biology and medicine. *Proc Natl Acad Sci U S*
1091 *A*, 111(45), 16219-16224.

1092

1093

